SURMONTIL
TRIMIPRAMINE MALEATE
Approval overview SURMONTIL is listed in Drugs@FDA under application 016792 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient TRIMIPRAMINE MALEATE Form and strength CAPSULE;ORAL - EQ 25MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor TEVA WOMENS Submission history Latest submission status date: 2014-09-30 00:00:00.
Structured Monograph
Clinical summary
Approval overview SURMONTIL is listed in Drugs@FDA under application 016792 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient TRIMIPRAMINE MALEATE Form and strength CAPSULE;ORAL - EQ 25MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor TEVA WOMENS Submission history Latest submission status date: 2014-09-30 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.